Second cancer among long-term survivors for Hodgkin's disease

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 2, 1998, Pages 373-378

  Nyandoto, Paul ^a   Muhonen, Timo ^a   Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adverse effects; Chemotherapy; Hodgkin's disease; Radiotherapy; Second cancer

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; SECOND CANCER;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; DACARBAZINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROCARBAZINE; RADIOTHERAPY DOSAGE; SURVIVORS; TIME FACTORS; VINBLASTINE; VINCRISTINE;

EID: 0032170206     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00217-X     Document Type: Article

References (29)

1. Rodriguez M.A., Fuller L.M., Zimmerman S.O., et al. Hodgkin's disease study of treatment intensities and incidences of second malignancies . Ann Oncol. 4:1993;125-131.
2. Mauch P.M., Kalish L.A., Marcus K.C., et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease long-term analysis of risk factors and outcome . Blood. 87:1996;3625-3632.
3. Bhatia S., Robinson L.L., Oberlin O., et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 334:1996;745-751.
4. Tucker M.A., Coleman C.N., Cox R.S. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 318:1988;76-81.
5. Beaty O. III, Hudson M.M., Greenwald C., et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol. 13:1995;603-609.
6. Boivin J.F., Hutchison G.B., Zauber A.G., et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst. 87:1995;732-741.
7. Valgussa P., Santoro A., Fossati-Bellani F., et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol. 6:1986;830-837.
8. Altman GD. Practical statistics for medical research. London: Chapman and Hall. 1991. p. 194-198, 368-371, 377-379.
9. Mauch P. Second malignancies after curative radiation therapy for good prognosis cancers. Int J Radiat Oncol Biol Phys. 33:1995;959-960.
10. Anderson H., Crowther D., Deakin D.P., Ryder W.D., Radford J.A. A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease 10 year follow-up . Ann Oncol. 2:1991;49-54.
11. Hunger S.P., Link M.P., Donaldson S.S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease the Stanford experience . J Clin Oncol. 12:1994;2160-2166.
12. Coleman C.N., Kaplan H.S., Cox R.S., et al. Leukemias, non-Hodgkin's lymphomas and solid tumors in patients treated for Hodgkin's disease. Cancer Surveys. 1:1982;733-744.
13. Coltman C.A., Dixon D.O. Second malignancies complicating Hodgkin's disease A Southwest Oncology Group 10-year follow up . Cancer Treat Rep. 66:1982;1023-1033.
14. Harris C.C. Chemicals and physical carcinogenesis advances and perspectives for the 1990s . Cancer Res. 51:(suppl):1991;5023-5044.
15. Weinstein I.B. The origins of human cancer molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment - twenty-seventh G.H.A. Clowes memorial award lecture . Cancer Res. 48:1988;4135-4143.
16. Kaplan HS, ed. Hodgkin's disease. 2nd ed. Cambridge, MA: Harvard University Press. 1980. p. 236-279.
17. Blattner W.A., Hoover R.N. Cancer in the immunosuppressed host. DeVita V.T. Jr, Hellman S., Rosenberg S.A. Cancer Principles and practice of oncology . 2nd ed. 1985;1999-2006 J. B. Lippincott, Philadelphia.
18. Meadows A.T., Obringer C.A., Marrero O., et al. Second malignant neoplasms following childhood Hodgkin's disease Treatment and splenectomy as risk factors . Med Pediatr Oncol. 17:1989;477-484.
19. Van Leeuwen F.E., Somers R., Hart A.A. Splenectomy in Hodgkin's disease and second leukemias. Lancet. 2:1987;210-211.
20. Robinson B.A., Colls B.M., Fitzharris B.M., Atkinson C.H. Second malignant neoplasms in patients with Hodgkin's disease. Aust NZ J Med. 24:1994;368-373.
21. Donaldson S.S., Kaplan H.S. Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep. 66:1982;977-989.
22. Tucker M.A., D'Angio G.J., Boice J.D., et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 317:1987;588-593.
23. Duhmke E., Diehl V., Loeffler M., et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 36:1996;305-310.
24. Mauch P., Tarbell N., Weinstein H., et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease prognostic factors in surgically staged patients treated with mantle and para-aortic irradiation . J Clin Oncol. 6:1988;1576-1583.
25. Tarbell N.J., Thompson L., Mauch P. Thoracic irradiation in Hodgkin's disease disease control and long-term complications . Int J Radiat Oncol Biol Phys. 18:1990;275-281.
26. Schewe K.L., Reavis J., Kun L.E., Cox J.D. Total dose, fraction size, and tumor volume in the local control of Hodgkin's disease. Int J Radiat Oncol Biol Phys. 15:1988;25-28.
27. Vijayakumar S., Myrianthopoulos L.C. An updated dose-response analysis in Hodgkin's disease. Radiother Oncol. 24:1992;1-13.
28. Duggan D., Petroni G., Johnson J., et al. MOPP/ABV versus ABVD for advanced Hodgkin's disease - a preliminary report of CALGB 8952 ( with SWOG, ECOG, NCIC ). (Abstr.) Proc Am Soc Clin Oncol. 16:1997;12a.
29. Carde P., Noordijk E.M., Hagenbeek J.C., et al. Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP/IF) over subtotal nodal irradiation (STNI) in favorable clinical Stage (CS) I-II Hodgkin's disease the EORTC-GPMC H7F randomized trial . (Abstr.) Proc Am Soc Clin Oncol. 16:1997;13a.